- Trials with a EudraCT protocol (66)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
66 result(s) found for: Whole Language.
Displaying page 1 of 4.
EudraCT Number: 2021-000781-15 | Sponsor Protocol Number: COVFATI | Start Date*: 2021-12-14 |
Sponsor Name:Amsterdam UMC VUmc | ||
Full Title: Neuroinflammation and post-infectious fatigue in individuals with and without Covid-19 | ||
Medical condition: Chronic fatigue after COVID-19 infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001775-20 | Sponsor Protocol Number: CHDR1644 | Start Date*: 2018-07-12 |
Sponsor Name:Centre for Human Drug Research | ||
Full Title: Immunomonitoring of tacrolimus in healthy volunteers | ||
Medical condition: Immunesuppression | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002174-30 | Sponsor Protocol Number: B3D-US-GHCV | Start Date*: 2005-09-09 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: The Use of Nuclear Scintigraphy to Evaluate the Anabolic Effects of Teriparatide on the Skeleton in Postmenopausal Women in Osteoporosis | ||
Medical condition: Oesteoporosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004853-26 | Sponsor Protocol Number: T315/2018 | Start Date*: 2019-03-25 | ||||||||||||||||
Sponsor Name:Turku University Hospital | ||||||||||||||||||
Full Title: The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic prostate cancer | ||||||||||||||||||
Medical condition: Metastatic prostate cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: FI (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005995-14 | Sponsor Protocol Number: 3133K1-3001-WW(B2521002) | Start Date*: 2009-05-29 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disea... | |||||||||||||
Medical condition: Alzheimer Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005994-79 | Sponsor Protocol Number: 3133K1-3000-WW | Start Date*: 2008-05-13 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development | |||||||||||||
Full Title: Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co... | |||||||||||||
Medical condition: Enfermedad de Alzheimer Alzheimer Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004619-31 | Sponsor Protocol Number: 2819-MA-1002 | Start Date*: 2014-09-01 | |||||||||||
Sponsor Name:Astellas Pharma Europe Ltd. | |||||||||||||
Full Title: A phase IIIb/IV randomized, controlled, open label, parallel group study to compare the efficacy of vancomycin therapy to extended duration fidaxomicin therapy in the sustained clinical cure of Clo... | |||||||||||||
Medical condition: Clostridium Difficile Infection (CDI) also known as C. difficile-associated diarrhoea (CDAD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) GB (Completed) CZ (Completed) DK (Completed) DE (Completed) IT (Completed) GR (Completed) SI (Completed) HU (Completed) IE (Completed) AT (Completed) BE (Completed) PT (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015525-37 | Sponsor Protocol Number: D1950C00006 | Start Date*: 2010-01-27 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: Safety, Tolerability and Pharmacokinetics of 3 Dose regimens of AZD1446 vs. Placebo as an Add-on Treatment to Donepezil: A Multi-centre, Double-blind, Randomised, Placebo controlled, Parallel group... | |||||||||||||
Medical condition: Patients with mild to moderate Alzheimer's Desease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005529-34 | Sponsor Protocol Number: TRx-237-007 | Start Date*: 2012-12-28 | |||||||||||
Sponsor Name:TauRx Therapeutics Ltd | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotem... | |||||||||||||
Medical condition: behavioral variant Frontotemporal Dementia (bvFTD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) NL (Completed) IT (Completed) FI (Completed) PL (Completed) ES (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002531-29 | Sponsor Protocol Number: NaturalDCformCRPC | Start Date*: 2014-10-30 |
Sponsor Name:Radboud University Medical Centre Nijmegen | ||
Full Title: A randomized phase IIa study: natural dendritic cells for immunotherapy of chemo-naive metastatic castration-resistant prostate cancer patients | ||
Medical condition: Asymptomatic or minimally symptomatic, chemo-naive mCRPC patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000445-39 | Sponsor Protocol Number: ACI-24-1801 | Start Date*: 2018-06-19 | |||||||||||
Sponsor Name:AC Immune SA | |||||||||||||
Full Title: A Phase II Double-Blind, Randomized, Placebo-Controlled, Adaptive Design Study to Assess the Safety, Tolerability, Immunogenicity and Target Engagement of ACI-24 Formulations in Patients with Mild ... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007134-19 | Sponsor Protocol Number: GAM10-04 | Start Date*: 2009-01-14 |
Sponsor Name:Octapharma AG | ||
Full Title: Prospective 24-week, double-blind, randomized, placebo-controlled, multicenter study evaluating safety and change in efficacy-related surrogate parameters in patients with dementia of the Alzheimer... | ||
Medical condition: mild to moderate Alzheimer´s disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005344-17 | Sponsor Protocol Number: CBDV_2014 | Start Date*: 2015-08-21 |
Sponsor Name:Department of Anesthesiology and Operative Intensive Care Medicine, Charité (CBF) | ||
Full Title: Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study. | ||
Medical condition: Chronic painful HIV-associated neuropathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001691-21 | Sponsor Protocol Number: GR-OG-279239-02 | Start Date*: 2016-05-17 | |||||||||||
Sponsor Name:Genera Research Ltd | |||||||||||||
Full Title: SAFETY, TOLERABILITY, rhBMP6 PHARMACOKINETICS AND BONE HEALING EFFECT OF A SINGLE DOSE OF OSTEOGROW (rhBMP6 IN AUTOLOGOUS WHOLE BLOOD COAGULUM DERIVED [WBCD] CARRIER) IN ADULT PATIENTS TREATED BY H... | |||||||||||||
Medical condition: Osteoarthritis of the medial knee joint compartment and/or symptomatic varus deformity. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005101-21 | Sponsor Protocol Number: GR-OG-279239-01 | Start Date*: 2014-12-22 | |||||||||||
Sponsor Name:Genera Research Ltd | |||||||||||||
Full Title: Safety, tolerability, systemic pharmacokinetics and efficacy of a single dose of Osteogrow (rhBMP6 in autologous Whole Blood Coagulum Derived [WBCD] carrier) delivered locally to the fracture site ... | |||||||||||||
Medical condition: Distal radius fracture. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002976-28 | Sponsor Protocol Number: CCNP520A2202J | Start Date*: 2017-05-16 | |||||||||||
Sponsor Name:Novartis Farmacéutica S.A. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease ... | |||||||||||||
Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) FI (Prematurely Ended) IS (Completed) PT (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000029-28 | Sponsor Protocol Number: P3-IMU-838-RMS-02 | Start Date*: 2022-09-05 | |||||||||||
Sponsor Name:Immunic AG | |||||||||||||
Full Title: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2) | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002866-11 | Sponsor Protocol Number: TRx-237-015 | Start Date*: 2013-01-23 | |||||||||||
Sponsor Name:TauRx Therapeutics Ltd | |||||||||||||
Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease | |||||||||||||
Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012025-11 | Sponsor Protocol Number: 01373 | Start Date*: 2010-01-26 | |||||||||||
Sponsor Name:D-Pharm Ltd. | |||||||||||||
Full Title: A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus... | |||||||||||||
Medical condition: Acute Ischemic Stroke Stroke is the most common neurologic disorder and is the third leading cause of death in developed countries, after myocardial infarction and cancer. Stroke is the second l... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) AT (Prematurely Ended) SK (Completed) IT (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002987-14 | Sponsor Protocol Number: BN40423 | Start Date*: 2019-02-13 | |||||||||||
Sponsor Name:F.Hoffmann La-Roche Ltd | |||||||||||||
Full Title: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST ... | |||||||||||||
Medical condition: Huntington's disease (HD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) NL (Completed) AT (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
